GFPA exhibited strong anti-obesity effects via the modulation of chronic inflammation through Toll-like receptor 4/nuclear factor kappa-B signaling, which supports the use of GFPA for the treatment of obesity. The gene discussed is TLR4; the disease is obesity due to melanocortin 4 receptor deficiency.